Major effects on blood-retina barrier passage by minor alterations in design of polybutylcyanoacrylate nanoparticles

You, Qing; Hopf, Talea; Hintz, Werner; Rannabauer, Stefan; Voigt, Nadine; Wachem, Berend van; Henrich‐Noack, Petra; Sabel, Bernhard A.

doi:10.1080/1061186x.2018.1531416

Cited by 15 publications

(20 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A great variety of new nanoparticles (NPs), with specific features have been under intense investigation [1][2][3][4][5][6][7][8]. Also, there are many studies on the effects of these nanoparticles within the human body [9][10][11][12], and a huge number of new nanodrugs have been approved for clinical use worldwide [13].…”

Section: Introductionmentioning

confidence: 99%

Molecular and Cellular Risk Assessment of Healthy Human Cells and Cancer Human Cells Exposed to Nanoparticles

Helal-Neto

Silva

Saldanha-Gama

et al. 2019

IJMS

View full text Add to dashboard Cite

Nanodrugs have in recent years been a subject of great debate. In 2017 alone, almost 50 nanodrugs were approved for clinical use worldwide. Despite the advantages related to nanodrugs/nanomedicine, there is still a lack of information regarding the biological safety, as the real behavior of these nanodrugs in the body. In order to better understand these aspects, in this study, we evaluated the effect of polylactic acid (PLA) nanoparticles (NPs) and magnetic core mesoporous silica nanoparticles (MMSN), of 1000 nm and 50 nm, respectively, on human cells. In this direction we evaluated the cell cycle, cytochemistry, proliferation and tubulogenesis on tumor cells lines: from melanoma (MV3), breast cancer (MCF-7, MDA-MB-213), glioma (U373MG), prostate (PC3), gastric (AGS) and colon adenocarcinoma (HT-29) and non-tumor cell lines: from human melanocyte (NGM), fibroblast (FGH) and endothelial (HUVEC), respectively. The data showed that an acute exposure to both, polymeric nanoparticles or MMSN, did not show any relevant toxic effects on neither tumor cells nor non-tumor cells, suggesting that although nanodrugs may present unrevealed aspects, under acute exposition to human cells they are harmless.

show abstract

Section: Introductionmentioning

confidence: 99%

Molecular and Cellular Risk Assessment of Healthy Human Cells and Cancer Human Cells Exposed to Nanoparticles

Helal-Neto

Silva

Saldanha-Gama

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…Further studies showed that a single parameter, such as size or zeta potential, could not determine if a given nanoparticle can pass the BRB. Actually, the interaction with the BRB seems to be determined by a combination of parameters . Finally, it should be clarified that these nanosystems are under development, and further improvements, namely in toxicity and scaling-up, still need to be done for the wider use of nanoparticles as part of a therapeutic methodology for ocular diseases. , …”

Section: Nanomedicine In Ocular Therapymentioning

confidence: 99%

“…Actually, the interaction with the BRB seems to be determined by a combination of parameters. 58 Finally, it should be clarified that these nanosystems are under development, and further improvements, namely in toxicity and scaling-up, still need to be done for the wider use of nanoparticles as part of a therapeutic methodology for ocular diseases. 51,59 Nanotechnology has been investigated for several applications in the treatment of ocular diseases.…”

Section: Nanomedicine In Ocular Therapymentioning

confidence: 99%

Emerging Trends in Nanomedicine for Improving Ocular Drug Delivery: Light-Responsive Nanoparticles, Mesoporous Silica Nanoparticles, and Contact Lenses

Rodrigues

Campos

Martins

et al. 2020

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Vision is the most dominant of our senses, and it is crucial in every stage of our lives. Ocular diseases, regardless of whether they cause vision impairment or not, lead to personal and financial hardships. The anatomy and physiology of the eye strongly limit the efficacy of current ocular drug delivery strategies. Nanotechnology has been the ground for the development of powerful strategies in several fields, namely in medicine. This review highlights emerging nanotechnology-based solutions for improving ocular drug delivery and thus the bioavailability and efficacy of drugs. We focus our review on ambitious but promising approaches currently emerging to leverage the efficacy of nanoparticle-based systems in ocular therapy: (i) light-responsive nanoparticles, which enable spatiotemporal control of drug release; (ii) mesoporous silica nanoparticles, which offer high surface area-to-volume ratio, simple surface modification, good biocompatibility, and improved bioavailability; and (iii) contact lenses, which serve as a compliant method of nanoparticles use and as drug delivery systems for the treatment of ocular diseases.

show abstract

“…However, low bioavailability of eye drops limits its clinical application for the treatment of retinoblastoma; unavoidable systemic toxicity and the inner BRB restrict the therapeutic efficacy of systemically administered chemotherapeutics. [ 7 ] All these concerns are compelling the development of a novel and non‐invasive drug delivery strategy for the treatment of retinoblastoma to reduce the side effects and increase the therapeutic efficacy.…”

Section: Introductionmentioning

confidence: 99%

Green Light‐Triggered Intraocular Drug Release for Intravenous Chemotherapy of Retinoblastoma

Long

Yang

et al. 2021

Advanced Science

View full text Add to dashboard Cite

Retinoblastoma is one of the most severe ocular diseases, of which current chemotherapy is limited to the repetitive intravitreal injections of chemotherapeutics. Systemic drug administration is a less invasive route; however, it is also less efficient for ocular drug delivery because of the existence of blood-retinal barrier and systemic side effects. Here, a photoresponsive drug release system is reported, which is self-assembled from photocleavable trigonal small molecules, to achieve light-triggered intraocular drug accumulation. After intravenous injection of drug-loaded nanocarriers, green light can trigger the disassembly of the nanocarriers in retinal blood vessels, which leads to intraocular drug release and accumulation to suppress retinoblastoma growth. This proof-of-concept study would advance the development of light-triggered drug release systems for the intravenous treatment of eye diseases.

show abstract

Major effects on blood-retina barrier passage by minor alterations in design of polybutylcyanoacrylate nanoparticles

Cited by 15 publications

References 33 publications

Molecular and Cellular Risk Assessment of Healthy Human Cells and Cancer Human Cells Exposed to Nanoparticles

Molecular and Cellular Risk Assessment of Healthy Human Cells and Cancer Human Cells Exposed to Nanoparticles

Emerging Trends in Nanomedicine for Improving Ocular Drug Delivery: Light-Responsive Nanoparticles, Mesoporous Silica Nanoparticles, and Contact Lenses

Green Light‐Triggered Intraocular Drug Release for Intravenous Chemotherapy of Retinoblastoma

Contact Info

Product

Resources

About